Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

256
Delayed Quote. Delayed BATS EUROPE - 05/22 05:29:50 pm
98.3250 CHF   +0.28%
05/22 NOVARTIS : announces two positive US phase III programs in COPD for ..
05/21DJFor CVS, Big Bet On Pricey Medicines
05/21DJCVS to Buy Omnicare for $10.4 Billion
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVARTIS AG
04/23DJNovartis Begins to See Benefits of Overhaul -- 2nd Update
04/23 CSL : Gordon Naylor to lead CSL's Global Influenza Vaccine Business
04/23DJNovartis Begins to See Benefits of Overhaul -- Update
04/23 NOVARTIS : Divestment gains boost net earnings at drug company Novartis
04/23DJNovartis Begins to See Benefits of Overhaul
04/23DJNovartis Profit Boosted by Disposals
04/23 NOVARTIS : confirms 2015 guidance after Q1 profit beat
04/23 NOVARTIS : delivered sales growth (cc), significant margin expansion (cc) and st..
04/23 NOVARTIS : Gordon Naylor to lead CSL's Global Influenza Vaccine Business
04/22DJMeet Pharma's Newest Movers and Shakers, Driving M&A
04/22DJMeet Pharma's Newest Movers and Shakers, Driving M&A
04/22 NOVARTIS : Patent Application Titled "Salt(S) of 7-Cyclopentyl-2-(5-Piperazin-1-..
04/22 DIPLOMAT PHARMACY : to Dispense Novartis Drug, JADENU™
04/22DJCSL Says CFO Naylor to Lead Influenza-Vaccine Business
04/22 NOVARTIS : Data at AAN showed Gilenya high efficacy in achieving 'no evidence of..
04/22 NOVARTIS : CorTechs Labs Enters into Agreement with Novartis Pharma
04/21DJAmgen Reports Higher Earnings, Outlook -- Update
04/21DJAmgen Posts 51% Rise in Profit, Boosts Outlook
04/21DJAmgen Posts 51% Rise in Profit, Boosts 2015 Outlook
04/21DJTeva Offers to Buy Mylan for $40 Billion -- 5th Update
04/21DJTeva Offers to Buy Mylan for $40 Billion -- 4th Update
04/21DJEREZ VIGODMAN : Teva Offers to Buy Mylan for $40 Billion -- 3rd Update
04/21DJTeva Offers to Buy Mylan for $40 Billion -- 2nd Update
04/21 NOVARTIS : Celebrates 19th Annual Community Partnership Day With More Than 27,00..
04/21 NOVARTIS : Data at AAN showed Gilenya® high efficacy in achieving 'no evidence o..
04/21 NOVARTIS : Data at AAN showed Gilenya® high efficacy in achieving 'no evidence o..
04/20DJNovartis 1Q 2015 -- Forecast
04/18 GLAXOSMITHKLINE : layoffs will take time
04/17 FDA approves generic version of top-selling MS drug Copaxone
04/17 MOMENTA PHARMACEUTICALS : Announces FDA Approval of ANDA for Glatopa(TM) (glatir..
04/17 NOVARTIS : Sandoz receives FDA approval for GlatopaTM as the first generic compe..
04/17 NOVARTIS : Alcon receives FDA approval of new multifocal intraocular lens to tre..
04/17 NOVARTIS : Unlocking the promise of innovation
04/17 NOVARTIS : Unlocking the promise of innovation
04/16 NOVARTIS : Unlocking the promise of innovation
04/16 CSL : Patent Application Titled "Method of Treatment of Philadelphia Chromosome ..
04/16DJFDA Approves Generic Multiple-Sclerosis Drug by Novartis's Sandoz and Momenta..
04/16DJFDA Approves Novartis and Momenta's Generic Multiple-Sclerosis Drug
04/16 NOVARTIS : Sandoz receives FDA approval for GlatopaTM as the first generic compe..
04/16 NOVARTIS : Sandoz receives FDA approval for GlatopaTM as the first generic compe..
04/16 NOVARTIS : R&D builds healthier China
04/16 NOVARTIS : R&D builds healthier China
04/16 NOVARTIS : Alcon receives FDA approval of new multifocal intraocular lens to tre..
04/16 NOVARTIS : Alcon receives FDA approval of new multifocal intraocular lens to tre..
04/15 AMGEN : FDA approves new type of heart failure drug from Amgen
04/15DJPfizer Breast-Cancer Drug Study Meets Primary Endpoint -- Update
04/15DJPfizer Breast-Cancer Drug Study Meets Primary Endpoint
04/15 NOVARTIS : Data in The Lancet show Novartis drug Arzerra® plus chlorambucil impr..
04/15 NOVARTIS : Data in The Lancet show Novartis drug Arzerra® plus chlorambucil impr..
04/14 NOVARTIS : Receives US Patent and Trademark Office 2015 ‘Patents for Human..
04/14 NOVARTIS : Gilenya data at AAN to highlight Novartis leadership in innovation wi..
04/13 NOVARTIS : Gilenya® data at AAN to highlight Novartis leadership in innovation w..
04/13 NOVARTIS : Gilenya® data at AAN to highlight Novartis leadership in innovation w..
04/09 NOVARTIS : "Process for the Manufacture of Cyclic Undecapeptides" in Patent Appl..
04/08 Generic drugmaker Mylan offers $29 billion for Perrigo
04/08 NOVARTIS : Patent Issued for Polymerizable Chain-Extended Polysiloxanes with Pen..
04/08 Patent Issued for Correction of Check Processing Defects
04/08 NOVARTIS : $65,202 Federal Contract Awarded to Alcon Laboratories
04/07 NOVARTIS : With patent dispute settled, Penn and Novartis can push ahead with im..
04/07 NOVARTIS : New therapeutic option now available for select treatment resistant l..
04/06 JUNO THERAPEUTICS : Announces Patent Litigation Settlement
04/06DJBristol-Myers Invests in uniQure in Heart-Disease Pact -- 2nd Update
04/06DJJuno Therapeutics Settles Patent Dispute With Novartis
04/06 NOVARTIS : Juno Therapeutics Announces Patent Litigation Settlement
04/05 NOVARTIS : FDA Approves Jadenu for Treatment for Patients With Chronic Iron Over..
04/03DJBayer's CEO Injects a Dose of U.S. Risk-Taking
04/03DJAt Bayer, A Dose Of US Risk-Taking
04/03 NOVARTIS : Alcon Research Assigned Patent
04/02 NOVARTIS : GSK to establish global vaccines R&D centre in the US | GSK
04/02 NOVARTIS : GSK statement on meningitis vaccination in the UK | GSK
04/02 NOVARTIS : Cheaper eye drugs claim
04/02 NOVARTIS : Cheaper eye drugs claim
04/02 NOVARTIS : GSK to establish global vaccines R%7ED centre in the US
04/01 Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer
04/01 NOVARTIS : Nexvet Biopharma Appoints Dr. George Gunn as Chairman
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials